Sp1059
THE CLINICAL VALUE OF BIOMARKER-BASED APPROACHES FOR THE EVALUATION AND MANAGEMENT OF IRRITABLE BOWEL SYNDROME: PRICE VS. PRECISION
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
DDW attendees will have the opportunity to learn about recent developments in biomarker-discovery for FGID/DGBI and Neurogastroenterology. Speakers will cover investigational and evolving biomarkers, practical utilization of biomarkers, and updates on biomarkers that are further down the pipeline and may be available for broader use in clinical practice and clinical research. Discuss novel and investigational biomarkers in functional gastrointestinal disorders (disorders of gut-brain interaction) Recognize currently available biomarkers and their potential applications in clinical practice, their strengths, and their limitations. Review the path to biomarker discovery and their role in enhancing patient care, highlighting challenges and future goals.
DDW attendees will have the opportunity to learn about recent developments in biomarker-discovery for FGID/DGBI and Neurogastroenterology. Speakers will cover investigational and evolving biomarkers, practical utilization of biomarkers, and updates on biomarkers that are further down the pipeline and may be available for broader use in clinical practice and clinical research. Discuss novel and investigational biomarkers in functional gastrointestinal disorders (disorders of gut-brain interaction) Recognize currently available biomarkers and their potential applications in clinical practice, their strengths, and their limitations. Review the path to biomarker discovery and their role in enhancing patient care, highlighting challenges and future goals.
Presenter
Mayo Clinic College of Medicine
Tracks
Related Products
PHARMACOGENETIC INTERACTIONS OF MEDICATIONS ADMINSTERED FOR WEIGHT LOSS IN ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
BACKGROUND: Sound evidence support the effectiveness of the transoral outlet reduction (TORe) with full-thickness endoscopic suturing (FTS) or argon plasma coagulation (APC) alone to address post-RYGB weight regain…
ABNORMAL GI MOTILITY IS A MAJOR FACTOR IN EXPLAINING SYMPTOMS IN PATIENTS WITH DGBI
A session focusing on recent advances in our understanding of the complex pathophysiology of disorders of gut-brain interaction (DGBI)…
MACHINE-LEARNING DRIVEN, FULL PHENOTYPE MODEL AND SURROGATE POLYGENIC RISK SCORE MODEL FOR APPETITE PREDICT RESPONSE TO GLP-1 RECEPTOR AGONIST IN PATIENTS WITH OBESITY
Background: Transoral outlet reduction endoscopy (TORe) has been shown to be effective in managing weight regain after Roux-en-Y gastric bypass (RYGB), as has the glucagon-like peptide-1 agonist, liraglutide. However, the effect of adjunctive liraglutide after TORe has yet to be assessed…
